Litigation Details for Rochester Drug Co-Operative, Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
✉ Email this page to a colleague
Rochester Drug Co-Operative, Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-06-22 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 28:1337sc Sherman-Clayton Act | Assigned To | Alvin K. Hellerstein |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,294,197; 6,395,728 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Rochester Drug Co-Operative, Inc. v. Novartis Pharmaceuticals Corporation
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Rochester Drug Co-Operative, Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-22 | 1 | Complaint | follow-on patents, U.S. Patent Nos. 6,294,197 (“the ‘197 Patent”) and 6,395,728 (the ‘728 Patent), which… Exforge: the ‘578 Patent; the ‘197 Patent; and the ‘728 Patent. The ‘578 Patent, which disclosed and… the ‘578 Patent expired on September 21, 2012. Neither the ‘197 Patent nor the ‘728 Patent afforded … the ’728 Patent, and is therefore prior art to the ‘728 Patent. The ‘904 Prior Art Patent is titled …exclusivities associated with U.S. Patent No. 5,399,578 (“the ‘578 Patent”), which covered the active ingredient | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
